The Enterprise Value as of November 2024 (TTM) for Amicus Therapeutics, Inc. (FOLD) is 3.10B

According to Amicus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.10B. This represents a change of -16.48% compared to the average of 3.71B of the last 4 quarters.

Amicus Therapeutics, Inc. (FOLD) Historical Enterprise Value (quarterly & annually)

How has FOLD Enterprise Value performed in the past?

The mean historical Enterprise Value of Amicus Therapeutics, Inc. over the last ten years is 2.68B. The current 3.10B Enterprise Value has changed 11.44% with respect to the historical average. Over the past ten years (40 quarters), FOLD's Enterprise Value was at its highest in in the December 2020 quarter at 6.26B. The Enterprise Value was at its lowest in in the December 2016 quarter at 635.70M.

Amicus Therapeutics, Inc. (FOLD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Amicus Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Amicus Therapeutics, Inc. (FOLD) Average Enterprise Value

How has FOLD Enterprise Value performed in the past?

The current Enterprise Value of Amicus Therapeutics, Inc. (FOLD) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Amicus Therapeutics, Inc. (FOLD) Enterprise Value vs. Peers

How is FOLD’s Enterprise Value compared to its peers?

Amicus Therapeutics, Inc.’s Enterprise Value is less than Incyte Corporation (12.55B), less than Denali Therapeutics Inc. (3.52B), less than argenx SE (35.17B), greater than Harmony Biosciences Holdings, Inc. (1.74B), less than Ultragenyx Pharmaceutical Inc. (4.24B), less than Crinetics Pharmaceuticals, Inc. (4.93B), greater than Arvinas, Inc. (1.69B), less than Revolution Medicines, Inc. (9.43B), greater than Kura Oncology, Inc. (807.00M), greater than Mineralys Therapeutics, Inc. (523.81M), less than Legend Biotech Corporation (7.40B), less than Cytokinetics, Incorporated (6.54B), greater than Inhibrx Biosciences, Inc. (9.32M), greater than DICE Therapeutics, Inc. (1.82B), greater than Edgewise Therapeutics, Inc. (3.01B), less than Karuna Therapeutics, Inc. (12.43B), greater than Dyne Therapeutics, Inc. (2.51B), greater than Mereo BioPharma Group plc (496.22M), less than Blueprint Medicines Corporation (6.36B), greater than Agios Pharmaceuticals, Inc. (2.98B), greater than Day One Biopharmaceuticals, Inc. (963.46M), less than BioMarin Pharmaceutical Inc. (12.17B),

Build a custom stock screener for Amicus Therapeutics, Inc. (FOLD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amicus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Amicus Therapeutics, Inc. (FOLD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Amicus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.